Authors: Wigginton, JM Park, JW Gruys, ME Young, HA Jorcyk, CL Back, TC Brunda, MJ Strieter, RM Ward, J Green, JE Wiltrout, RH

Citation: Jm. Wigginton et al., Complete regression of established spontaneous mammary carcinoma and the therapeutic prevention of genetically programmed neoplastic transition by IL-12/pulse IL-2: Induction of local T cell infiltration, Fas/Fas ligand geneexpression, and mammary epithelial apoptosis, J IMMUNOL, 166(2), 2001, pp. 1156-1168

Authors: Wigginton, JM Gruys, E Geiselhart, L Subleski, J Komschlies, KL Park, JW Wiltrout, TA Nagashima, K Back, TC Wiltrout, RH

Citation: Jm. Wigginton et al., IFN-gamma and Fas/FasL are required for the antitumor and antiangiogenic effects of IL-12/pulse IL-2 therapy, J CLIN INV, 108(1), 2001, pp. 51-62

Authors: Gruys, ME Back, TC Subleski, J Wiltrout, TA Lee, JK Schmidt, L Watanabe, M Stanyon, R Ward, JM Wigginton, JM Wiltrout, RH

Citation: Me. Gruys et al., Induction of transplantable mouse renal cell cancers by streptozotocin: Invivo growth, metastases, and angiogenic phenotype, CANCER RES, 61(16), 2001, pp. 6255-6263

Authors: Lee, JK Sayers, TJ Brooks, AD Back, TC Young, HA Komschlies, KL Wigginton, JM Wiltrout, RH

Citation: Jk. Lee et al., IFN-gamma-dependent delay of in vivo tumor progression by Fas overexpression on murine renal cancer cells, J IMMUNOL, 164(1), 2000, pp. 231-239

Authors: Ito, D Back, TC Shakhov, AN Wiltrout, RH Nedospasov, SA

Citation: D. Ito et al., Mice with a targeted mutation in lymphotoxin-alpha exhibit enhanced tumor growth and metastasis: Impaired NK cell development and recruitment, J IMMUNOL, 163(5), 1999, pp. 2809-2815